Gian M. Novaro, MD

Gian M. Novaro, MD
Department of Cardiovascular Medicine, The Cleveland Clinic, Weston, Florida

Brian P. Griffin, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Brian P. Griffin, MD, Section of Cardiovascular Imaging, F15, Department of Cardiology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44122; e-mail: [email protected]

Dr. Novaro has indicated that he has received grant or research support from Pfizer Inc.

Dr. Griffin has indicated that he is on the speakers' bureau of the Merck corporation and has received grant or research support from Pfizer Inc.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Gian M. Novaro, MD
Department of Cardiovascular Medicine, The Cleveland Clinic, Weston, Florida

Brian P. Griffin, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Brian P. Griffin, MD, Section of Cardiovascular Imaging, F15, Department of Cardiology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44122; e-mail: [email protected]

Dr. Novaro has indicated that he has received grant or research support from Pfizer Inc.

Dr. Griffin has indicated that he is on the speakers' bureau of the Merck corporation and has received grant or research support from Pfizer Inc.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Gian M. Novaro, MD
Department of Cardiovascular Medicine, The Cleveland Clinic, Weston, Florida

Brian P. Griffin, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Address: Brian P. Griffin, MD, Section of Cardiovascular Imaging, F15, Department of Cardiology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44122; e-mail: [email protected]

Dr. Novaro has indicated that he has received grant or research support from Pfizer Inc.

Dr. Griffin has indicated that he is on the speakers' bureau of the Merck corporation and has received grant or research support from Pfizer Inc.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.